Platelet reactivity and formation of platelet-monocyte complexes in patients with chronic obstructive pulmonary disease (COPD)

Platelet reactivity and formation of platelet-monocyte complexes in patients with chronic obstructive pulmonary disease (COPD) - COPD reactivity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42526

Enrollment

Registered

2015-07-28

Start date

2015-10-12

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD chronic obstructive pulmonary disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study the COPD subjects must meet all of the following criteria: • >40 years • Bronchus obstruction detected by spirometry: FEV1/FVC ratio =10 pack years of smoking

Exclusion criteria

Exclusion criteria: • Use of aspirin or other platelet function inhibitors • Asthma • Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE) • Malignancies Regarding the control subjects the inclusion criteria described above do not apply, however the exclusion criteria do apply.

Design outcomes

Primary

Measure	Time frame
Parameters are platelet reactivity (platelet expression of the platelet activation marker CD62P (P-selectin) and activated fibrinogen receptor (aIIbβ3) upon stimulation with different platelet agonists), platelet-monocyte complexes, soluble markers of platelet activation and inflammatory cytokines and the relation of platelet activation to GOLD classification, exacerbation rate, smoking and lung function.	—

Measure

Time frame

Parameters are platelet reactivity (platelet expression of the platelet activation marker CD62P (P-selectin) and activated fibrinogen receptor (aIIbβ3) upon stimulation with different platelet agonists), platelet-monocyte complexes, soluble markers of platelet activation and inflammatory cytokines and the relation of platelet activation to GOLD classification, exacerbation rate, smoking and lung function.

—

Secondary

Measure	Time frame
See primairy outcomes.	—

Countries

Netherlands

Outcome results